SCHEDULE 13G/A: Wellington Management Discloses 3.9% Stake in Guardant Health, Inc.

Wellington Management Group LLP and its affiliates have disclosed a 3.9% beneficial ownership stake in Guardant Health, Inc. as of December 31, 2024, through an amended Schedule 13G filing.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP collectively reported beneficial ownership of 4,850,271 shares of Guardant Health, Inc. common stock.
• This ownership represents 3.9% of Guardant Health's outstanding common stock as of December 31, 2024.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change in their previously reported ownership or a new filing threshold.
• The shares are held by clients of various Wellington Investment Advisers, with Wellington Management Group LLP acting as the parent holding company.
• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Guardant Health, Inc.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G) and does not contain performance data or forward-looking statements from the issuer. The sentiment is neutral as it simply reports an institutional investor's stake.

Positives

• A major institutional investor, Wellington Management Group LLP, holds a significant stake, potentially indicating confidence in Guardant Health's long-term prospects and stability.

Future Outlook

NA

Industry Context

This filing indicates continued institutional investor interest in the healthcare and biotechnology sectors, specifically in precision oncology, as evidenced by Wellington Management's stake in Guardant Health, Inc. It reflects a routine disclosure of a significant investment by a major asset manager.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like Wellington Management may be viewed positively, potentially signaling confidence in the company's value and attracting further investor interest.

Key Dates

Keywords

Guardant Health, Wellington Management, Schedule 13G, beneficial ownership, common stock, institutional investor, healthcare, biotechnology, precision oncology